
Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund
pharmafile | March 12, 2020 | News story | Sales and Marketing | Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for locally advanced or metastatic urothelial carcinoma in patients who have previously undergone platinum-containing chemotherapy.
Data harvested during the drug’s availability via the Cancer Drugs Fund and submitted in support of the application could not adequately address the institute’s concerns over its long-term benefit.
Without certainty regarding this benefit, NICE could not judge the therapy to be a cost-effective use of NHS resources at the price currently offered. The drug costs £2,630 per 100mg vial, but even when this price is discounted it could not be considered within the NHS’ ability to pay.
As a result of this ruling and with the publishing of final guidance, NICE confirmed that Keytruda will no longer be available to new patients via the Cancer Drugs Fund. Patients already receiving the drug will continue to be able to access it however.
Urothelial carcinoma is the most common form of bladder cancer, accounting for 90% of cases.
Matt Fellows
Related Content

“That gap between innovation and delivery was what stood out to me most”
Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and …

Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study
People in their forties account for almost three-quarters of those who do not attend NHS …

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for …






